Jo Jung Ki, Shinn Sung Ho, Kim Kyu Shik, Moon Hong Sang
Department of Urology, Hanyang University College of Medicine, Seoul, Korea.
Department of Thoracic and Cardiovascular Surgery, Cheju Halla General Hospital, Jeju, Korea.
Int Neurourol J. 2021 Dec;25(4):347-354. doi: 10.5213/inj.2040412.206. Epub 2021 Jan 27.
Benign prostatic hyperplasia (BPH) is associated with lower urinary tract symptoms and negatively affects the quality of life. We aimed to investigate the treatment pattern of BPH in South Korea.
Information on treatment modalities and diagnoses of BPH was obtained from the Health Insurance Review and Assessment Service-Aged Patient Sample. Data on BPH patients aged ≥60 years from 2012 to 2016 were obtained. We surveyed the treatment pattern of BPH, including the types of drugs used and surgeries performed, according to the type of institution.
In this study, 18,260-24,657 BPH patients treated between 2012 and 2016 were included. The number of patients showed an increasing pattern, and drug therapy was the major treatment method used for BPH (98.77%). Moreover, the pattern of increased pharmacotherapy use for BPH was reinforced by the increasing number of patients. Prescription of α-blockers only was dominant in this cohort (45.7%). Transurethral resection of the prostate (TURP) was the most commonly used surgical treatment for BPH (53.6%), but it showed a decreasing pattern over time. In contrast, holmium laser enucleation of the prostate (HoLEP) showed an increase from 19.4% to 39.7%.
The most common treatment for BPH was drug therapy, predominantly only α-blocker therapy. The surgical treatment trend has changed from TURP to HoLEP.
良性前列腺增生(BPH)与下尿路症状相关,对生活质量有负面影响。我们旨在调查韩国BPH的治疗模式。
从健康保险审查和评估服务机构的老年患者样本中获取BPH的治疗方式和诊断信息。获取了2012年至2016年年龄≥60岁的BPH患者的数据。我们根据机构类型调查了BPH的治疗模式,包括所用药物类型和所进行的手术。
本研究纳入了2012年至2016年期间接受治疗的18260 - 24657例BPH患者。患者数量呈增加趋势,药物治疗是BPH的主要治疗方法(98.77%)。此外,BPH药物治疗使用增加的模式因患者数量增加而得到强化。仅α受体阻滞剂的处方在该队列中占主导(45.7%)。经尿道前列腺切除术(TURP)是BPH最常用的手术治疗方法(53.6%),但随时间呈下降趋势。相比之下,钬激光前列腺剜除术(HoLEP)从19.4%增至39.7%。
BPH最常见的治疗方法是药物治疗,主要是仅α受体阻滞剂治疗。手术治疗趋势已从TURP转变为HoLEP。